Immuno-oncology 22/01/2018 15 Immuno-oncology Biotechs to Watch in 2018 We’re keeping tabs on the innovators and disruptors for you.
Cell and Gene Therapy 22/01/2018 Regenerative Medicine Contract Manufacturing Organisations in Japan A summary of all of the regenerative medicine CMOs in Japan is presented in this infographic
Cell and Gene Therapy 22/01/2018 Cell and Gene Therapy Manufacturing Capacities in Europe 2017 Without capacity; manufacturing expertise; innovation and partnerships, advanced therapies cannot be commercialised nor delivered to patients ...
Cell and Gene Therapy 22/01/2018 Understanding the layers of complexity and working towards full... One of the main barriers to commercial viability for ATMPs is the supply chain, which contributes significantly to the overall cost of goods ...
Cell and Gene Therapy 18/01/2018 GMP Cell and Gene Therapy Manufacturing in the UK: Facilities,... The cell and gene therapy catapult review of MHRA licensed GMP manufacturing facilities in the UK provides an insightful picture of the capability...
Cell and Gene Therapy 11/01/2018 CRO Selection for Advanced Therapies How do you find the perfect CRO?
Investment for Advanced Therapies 16/11/2017 An Investor’s Outlook on the Advanced Therapies Industry with... William Podd gives his perspective on investing in advanced therapies and advice for investors and biotechs alike
Cell and Gene Therapy 08/03/2017 Interview: Understanding development processes to ensure product... DR Felicia Rosenthal, CEO, Cellgenix discusses raw material for cell and tissue-based products, GMP manufacturing considerations and scale-up...
Cell and Gene Therapy 08/03/2017 Quantitative Understandings of Risk in Cell and Gene Therapies What is risk? How can we accurately understand risk and apply this understanding to inform solutions for investors? There are no easy answers to...
Immuno-oncology 06/03/2017 Systematic Automation of an Autologous Cellular Immunotherapy... As more and more approvals of immuno-oncology therapies become reality, how will these therapies be efficiently and sustainably scaled up and...
Immuno-oncology 08/02/2017 Anti-angiogenic Targets and Checkpoint Inhibitors as a Potential... A combination therapy trial case study: ramucirumab, an immunoglobulin G1 VEGFR-2 monoclonal antibody
Immuno-oncology 08/02/2017 Top 20 Disruptive Projects in Drug Development Data Analytics A round-up of the 20 projects with the greatest potential to develop life science research
Immuno-oncology 07/02/2017 Innovation in the Development of Cancer Vaccines Cancer vaccines have gained increasing popularity since the US FDA approved the first cancer vaccine, sipuleucel-T, in 2010 and then approved the...
Immuno-oncology 07/02/2017 Interview: Developing Novel TNF/TNFR-based Compounds in the Fight... Thomas Hoeger, Ph.D., has been Chief Executive Officer of Apogenix since November 2005. Previously, he worked as a biotech analyst for DZ Bank in...
Immuno-oncology 03/02/2017 Bioinformatics Modelling for Immunotherapy Precision medicine requires the delivery of individually adapted medical care based on the genetic characteristics of each patient and their tumour...
